Biocon gets USFDA nod for breast cancer biosimilar PebrilzoBiocon Ltd has announced receiving US FDA approval for their biosimilar Pebrilzo, which treats HER2-positive breast cancer. This milestone ...
Biocon settles US patent dispute with Roche's Genentech, eyes 2027 Perjeta biosimilar launchBiocon announced a settlement with Genentech over its biosimilar, Pebrilzo, of the cancer drug Perjeta. The agreement allows Biocon to laun...
Biocon clears path for cancer drug launchBiocon has finalized a global settlement and license agreement with Genentech for its drug Pebrilzo. This agreement addresses all ongoing l...